phosphorylcholine has been researched along with Glial Cell Tumors in 27 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "ErPC (40 mg/kg) was given to C6 glioma-bearing rats either as a single intracarotid bolus injection in the presence or absence of 1- O-pentylglycerol (300 m M) or as an intracarotid infusion in conjunction with bradykinin." | 7.71 | Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M, 2002) |
| "In the present study we investigate the effect of exogenous sphingosine, sphingosine 1-phosphate and sphingosylphosphorylcholine on phospholipase D (PLD) activity in glioma C6 cells." | 7.70 | Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. ( Barańska, J; Bobeszko, M; Dygas, A; Sidorko, M, 1999) |
| "The effect of sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate on L-[U-14C]serine incorporation into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was investigated in intact glioma C6 cells." | 7.70 | Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. ( Barańska, J; Wójcik, M, 1999) |
| "Treatment with miltefosine resulted in increase in Ras, extracellular signal-regulated kinase (ERK) and p38MAPK activity." | 5.35 | Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation. ( Koul, N; Sen, E; Sharma, V; Tewari, R, 2008) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 5.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Erucylphosphocholine (ErPC) is a promising anti-neoplastic drug for the treatment of malignant brain tumours." | 5.31 | Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation. ( Eibl, H; Erdlenbruch, B; Heinemann, D; Jünemann, A; Kugler, W; Lakomek, M, 2002) |
| "Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas." | 3.91 | In vivo Metabolic Profiles as Determined by ( Bähr, O; Franz, K; Hattingen, E; Pilatus, U; Steinbach, J; Wenger, KJ, 2019) |
| "ErPC (40 mg/kg) was given to C6 glioma-bearing rats either as a single intracarotid bolus injection in the presence or absence of 1- O-pentylglycerol (300 m M) or as an intracarotid infusion in conjunction with bradykinin." | 3.71 | Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M, 2002) |
| "The authors sought to compare 1H magnetic resonance spectroscopy (MRS) spectra from extracts of low-grade and high-grade gliomas, especially with respect to the signals of choline-containing compounds." | 3.70 | Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. ( Berry, I; Breil, S; Delisle, MB; Gilard, V; Malet-Martino, M; Manelfe, C; Ranjeva, JP; Sabatier, J; Terral, C; Tremoulet, M, 1999) |
| "In the present study we investigate the effect of exogenous sphingosine, sphingosine 1-phosphate and sphingosylphosphorylcholine on phospholipase D (PLD) activity in glioma C6 cells." | 3.70 | Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. ( Barańska, J; Bobeszko, M; Dygas, A; Sidorko, M, 1999) |
| "The effect of sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate on L-[U-14C]serine incorporation into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was investigated in intact glioma C6 cells." | 3.70 | Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. ( Barańska, J; Wójcik, M, 1999) |
| "It has been found that sphingosine and sphingosylphosphorylcholine (amphiphilic cations) have a stimulatory, and cholesterol 3-sulfate (an amphiphilic anion), an inhibitory, effect on [14C]serine incorporation into phosphatidylserine in glioma C6 and rat liver microsomes." | 3.69 | Serine base exchange enzyme activity is modulated by sphingosine and other amphiphilic compounds: possible role of positive charge in increasing the synthesis of phosphatidylserine. ( Banasiak, M; Barańska, J; Czarny, M; Stepkowski, D; Wiktorek-Wójcik, M, 1997) |
| "Treatment with miltefosine resulted in increase in Ras, extracellular signal-regulated kinase (ERK) and p38MAPK activity." | 1.35 | Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation. ( Koul, N; Sen, E; Sharma, V; Tewari, R, 2008) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 1.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Erucylphosphocholine (ErPC) is a promising anti-neoplastic drug for the treatment of malignant brain tumours." | 1.31 | Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation. ( Eibl, H; Erdlenbruch, B; Heinemann, D; Jünemann, A; Kugler, W; Lakomek, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Chao, Y | 1 |
| Zhao, H | 1 |
| Zhou, X | 1 |
| Zhang, F | 1 |
| Zhang, Z | 1 |
| Li, Z | 1 |
| Pan, J | 1 |
| Wang, J | 1 |
| Chen, Q | 1 |
| Liu, Z | 1 |
| Sandbhor, P | 1 |
| Goda, JS | 1 |
| Mohanty, B | 1 |
| Chaudhari, P | 1 |
| Dutt, S | 1 |
| Banerjee, R | 1 |
| Sola-Barrado, B | 1 |
| M Leite, D | 1 |
| Scarpa, E | 1 |
| Duro-Castano, A | 1 |
| Battaglia, G | 1 |
| Ban, J | 1 |
| Li, S | 1 |
| Zhan, Q | 1 |
| Li, X | 1 |
| Xing, H | 1 |
| Chen, N | 1 |
| Long, L | 1 |
| Hou, X | 1 |
| Zhao, J | 1 |
| Yuan, X | 1 |
| Wang, N | 1 |
| Sun, P | 1 |
| Lv, M | 1 |
| Tong, G | 1 |
| Jin, X | 1 |
| Zhu, X | 1 |
| Becher, OJ | 2 |
| Millard, NE | 1 |
| Modak, S | 1 |
| Kushner, BH | 1 |
| Haque, S | 1 |
| Spasojevic, I | 1 |
| Trippett, TM | 1 |
| Gilheeney, SW | 1 |
| Khakoo, Y | 1 |
| Lyden, DC | 1 |
| De Braganca, KC | 1 |
| Kolesar, JM | 1 |
| Huse, JT | 2 |
| Kramer, K | 1 |
| Cheung, NV | 1 |
| Dunkel, IJ | 1 |
| Wenger, KJ | 1 |
| Hattingen, E | 1 |
| Franz, K | 1 |
| Steinbach, J | 1 |
| Bähr, O | 1 |
| Pilatus, U | 1 |
| Swanson, KI | 1 |
| Clark, PA | 1 |
| Zhang, RR | 1 |
| Kandela, IK | 1 |
| Farhoud, M | 1 |
| Weichert, JP | 1 |
| Kuo, JS | 1 |
| Zhou, Z | 1 |
| Ho, SL | 1 |
| Singh, R | 1 |
| Pisapia, DJ | 1 |
| Souweidane, MM | 1 |
| Tewari, R | 1 |
| Sharma, V | 1 |
| Koul, N | 1 |
| Sen, E | 1 |
| Hambardzumyan, D | 1 |
| Walker, TR | 1 |
| Helmy, K | 1 |
| Nazarian, J | 1 |
| Albrecht, S | 1 |
| Hiner, RL | 1 |
| Gall, S | 1 |
| Jabado, N | 1 |
| MacDonald, TJ | 1 |
| Holland, EC | 2 |
| Mirbahai, L | 1 |
| Wilson, M | 1 |
| Shaw, CS | 1 |
| McConville, C | 1 |
| Malcomson, RD | 1 |
| Griffin, JL | 2 |
| Kauppinen, RA | 2 |
| Peet, AC | 1 |
| Erdlenbruch, B | 3 |
| Jendrossek, V | 2 |
| Kugler, W | 3 |
| Eibl, H | 3 |
| Lakomek, M | 3 |
| Jünemann, A | 1 |
| Heinemann, D | 1 |
| Lehtimäki, KK | 1 |
| Valonen, PK | 1 |
| Väisänen, TH | 1 |
| Gröhn, OH | 1 |
| Kettunen, MI | 1 |
| Vepsäläinen, J | 1 |
| Ylä-Herttuala, S | 1 |
| Nicholson, J | 1 |
| Naumann, U | 1 |
| Wischhusen, J | 1 |
| Weit, S | 1 |
| Rieger, J | 1 |
| Wolburg, H | 1 |
| Massing, U | 1 |
| Weller, M | 1 |
| Momota, H | 1 |
| Nerio, E | 1 |
| de la Peña, L | 1 |
| Burgan, WE | 1 |
| Carter, DJ | 1 |
| Hollingshead, MG | 1 |
| Satyamitra, M | 1 |
| Camphausen, K | 1 |
| Tofilon, PJ | 1 |
| Go, KG | 1 |
| Kamman, RL | 1 |
| Mooyaart, EL | 1 |
| Heesters, MA | 1 |
| Pruim, J | 1 |
| Vaalburg, W | 1 |
| Paans, AM | 1 |
| Gillies, RJ | 1 |
| Barry, JA | 1 |
| Ross, BD | 1 |
| Wiktorek-Wójcik, M | 1 |
| Banasiak, M | 1 |
| Czarny, M | 1 |
| Stepkowski, D | 1 |
| Barańska, J | 3 |
| Sabatier, J | 1 |
| Gilard, V | 1 |
| Malet-Martino, M | 1 |
| Ranjeva, JP | 1 |
| Terral, C | 1 |
| Breil, S | 1 |
| Delisle, MB | 1 |
| Manelfe, C | 1 |
| Tremoulet, M | 1 |
| Berry, I | 1 |
| Dygas, A | 1 |
| Sidorko, M | 1 |
| Bobeszko, M | 1 |
| Wójcik, M | 1 |
| Son, BC | 1 |
| Kim, MC | 1 |
| Choi, BG | 1 |
| Kim, EN | 1 |
| Baik, HM | 1 |
| Choe, BY | 1 |
| Naruse, S | 1 |
| Kang, JK | 1 |
| Zeller, WJ | 1 |
| Bauer, S | 1 |
| Remmele, T | 1 |
| Wowra, B | 1 |
| Sturm, V | 1 |
| Stricker, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma[NCT01106794] | 100 participants (Anticipated) | Observational | 2010-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Glial Cell Tumors
| Article | Year |
|---|---|
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Topics: Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Drug A | 2017 |
26 other studies available for phosphorylcholine and Glial Cell Tumors
| Article | Year |
|---|---|
Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma.
Topics: Animals; Antibodies; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Glioma; Immunotherapy; | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Combinatorial Intracellular Delivery Screening of Anticancer Drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Carriers; Drug Screening Assa | 2020 |
PMPC Modified PAMAM Dendrimer Enhances Brain Tumor-Targeted Drug Delivery.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Doxorubicin; Drug Carri | 2021 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
In vivo Metabolic Profiles as Determined by
Topics: Adult; Aged; Analysis of Variance; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Diagnosis, Diffe | 2019 |
Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Flow Cytometry; Fluorescent Dyes; Glioma; Heterograft | 2015 |
Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem.
Topics: Animals; Animals, Newborn; Brain Stem; Cell Line, Tumor; Cell Proliferation; Convection; Dasatinib; | 2015 |
Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Extracellu | 2008 |
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.
Topics: Animals; Brain Stem Neoplasms; Combined Modality Therapy; Disease Models, Animal; Genetic Engineerin | 2010 |
1H magnetic resonance spectroscopy metabolites as biomarkers for cell cycle arrest and cell death in rat glioma cells.
Topics: Amino Acids; Animals; Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cisplatin; G1 Phase; Glioma; | 2011 |
Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Glycerol; Injec | 2002 |
Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Caspases; Cell Death; Enzyme Activation; Enzyme Inhibito | 2002 |
Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Choline; Diffusion; Ganciclovir; Genet | 2003 |
Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; bcl-X Protein; Brain Neoplasms; Caspases; Cell Line, T | 2004 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Immunohistoc | 2006 |
Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography.
Topics: Aspartic Acid; Brain; Brain Chemistry; Brain Edema; Carbon Radioisotopes; Creatine; Deoxyglucose; Fl | 1995 |
In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells.
Topics: Animals; Carbon Isotopes; Cell Division; Choline; Ethanolamines; Glioma; Magnetic Resonance Spectros | 1994 |
Serine base exchange enzyme activity is modulated by sphingosine and other amphiphilic compounds: possible role of positive charge in increasing the synthesis of phosphatidylserine.
Topics: Animals; Cholesterol Esters; Glioma; Kinetics; Microsomes; Microsomes, Liver; Nitrogenous Group Tran | 1997 |
Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Choline; Female; Glioma; Humans; In Vitro Techniques; Magnetic Resonan | 1999 |
Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells.
Topics: Brain Neoplasms; Enzyme Activation; Glioma; Lysophospholipids; Phospholipase D; Phosphorylcholine; S | 1999 |
Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells.
Topics: Brain Neoplasms; Glioma; Homeostasis; Lysophospholipids; Phosphorylcholine; Sphingosine; Tumor Cells | 1999 |
Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy.
Topics: Adult; Aspartic Acid; Biopsy, Needle; Brain; Brain Neoplasms; Creatine; Diagnosis, Differential; Ene | 2001 |
Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell D | 2001 |
Interstitial chemotherapy of experimental gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Gl | 1990 |